Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization
in pterygium, preventing or retarding the progression of recurrence.